BCAB Expense Breakdown
BioAtla, Inc. (BCAB). Quarter ended 2023-09-30 · each product line is listed as filed.
- 2026-06-30: Total Program Expenses $2.35M; Personnel and Related $481.00K; Facilities and Other $373.00K; Equity Based Compensation $135.00K.
- 2025-06-30: Total Program Expenses $10.17M; Personnel and Related $2.15M; Facilities and Other $804.00K; Equity Based Compensation $567.00K.
Expenses by product
Research and development: each quarter (3 month)
| Quarter end | Total Program Expenses | Personnel and Related | Facilities and Other | Equity Based Compensation |
|---|---|---|---|---|
| 2026-06-30 | $2.35M | $481.00K | $373.00K | $135.00K |
| 2025-06-30 | $10.17M | $2.15M | $804.00K | $567.00K |
General and Administrative Expense: each quarter (3 month)
| Quarter end | Personnel and Related | Facilities and Other | Equity Based Compensation |
|---|---|---|---|
| 2026-06-30 | $727.00K | $1.72M | $485.00K |
| 2025-06-30 | $1.58M | $2.58M | $810.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |